Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) has been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $11.60.
IPSC has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Century Therapeutics in a research report on Tuesday, June 4th. Rodman & Renshaw began coverage on shares of Century Therapeutics in a report on Thursday, August 8th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Piper Sandler upped their price objective on shares of Century Therapeutics from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Monday, June 17th.
View Our Latest Stock Analysis on IPSC
Hedge Funds Weigh In On Century Therapeutics
Century Therapeutics Stock Down 5.5 %
Shares of Century Therapeutics stock opened at $1.56 on Thursday. The company’s fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $3.35. Century Therapeutics has a 12-month low of $1.28 and a 12-month high of $5.51. The firm has a market cap of $131.82 million, a PE ratio of -0.71 and a beta of 1.39.
Century Therapeutics (NASDAQ:IPSC – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.12. Century Therapeutics had a negative net margin of 9,742.41% and a negative return on equity of 59.74%. The company had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.55 million. As a group, sell-side analysts expect that Century Therapeutics will post -1.94 earnings per share for the current fiscal year.
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Recommended Stories
- Five stocks we like better than Century Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Brinker International’s Price Dip is an Appetizing Entry Point
- About the Markup Calculator
- 3 Stocks That Could Beat the September Blues
- What Does Downgrade Mean in Investing?
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.